TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzheimer's treatment Leqembi and the company's ...

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial ...

The company's U.S. headquarters are in the ON3 complex in Nutley and Clifton. Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records ...

Global cryptocurrency market capitalization is trading 7.4% lower at $2.86 trillion. One trader is curious if this is a higher low relative to last week’s low while another marks $80,000 as key ...

TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...

(AP Photo/Christophe Ena, Pool) “We’ve now agreed that the United Kingdom, along with France and possibly one or two others, will work with Ukraine on a plan to stop the fighting, and then we ...

(AP Photo/Christophe Ena) PSG’s Bradley Barcola celebrates scoring his side first goal during the French League One soccer match between Paris Saint-Germain and Lille, Saturday, March 1, 2025 at the ...

She defeated No. 7 seed Katie Volynets in the first round, and won two three-setters against Jodie Burrage and Ena Shibahara to reach the penultimate round -- saving a match point against the latter.

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Bitcoin rebounded 8% from its overnight low as some investors bought its dip below $79,000, although the largest crypto by market value looked wobbly, along with other risk-on assets, after U.S. and ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese drugmaker is reworking parts of its operations in the U.S. Eisai plans to ...